Vertex Pharma Stock - Analyst consensus and earnings outlook
22.06.2026 - 09:24:08 | ad-hoc-news.de
Edited by ad hoc news Earnings & Calendar Desk. Verified prior to publication on 06/22/2026, 07:22 UTC. Details in the imprint.
Vertex Pharma (US92532F1003) continues to be shaped by expectations around its cystic fibrosis franchise and late-stage pipeline. With no new company or regulatory headlines confirmed this morning, the focus turns to analyst consensus and the schedule for the next earnings release.
Background and data on Vertex Pharma stock
Key figures, news and regulatory filings on Vertex Pharma stock can be found in the dedicated topic section and on the company’s investor relations pages.
What the consensus shows
Analyst data compiled by several market platforms indicate that Vertex Pharma stock is broadly rated in the positive range, with a majority of brokers assigning Buy or equivalent ratings. Target prices cluster meaningfully above recent trading levels in many cases.
According to aggregated estimates, Wall Street expects further revenue growth driven mainly by cystic fibrosis therapies, supplemented by early contributions from newer programs over the coming years. Earnings per share are forecast to grow at a solid double-digit rate on average, supported by high margins.
Next earnings and calendar
Vertex customarily reports quarterly numbers after the US market close, with dates published in advance on its investor relations site. The next earnings release has not yet been formally fixed on the front page calendar but is expected around late July or early August based on prior years’ patterns.
Investors will again focus on the development of cystic fibrosis sales, progress of the pain and gene-editing programs, and any adjustments to full-year guidance if provided. Commentary on pricing, reimbursement and competitive dynamics will also be closely monitored.
How the company makes money
Vertex Pharma generates the bulk of its revenue from branded medicines for cystic fibrosis, led by its combination therapy franchise, and is investing heavily in a pipeline spanning pain, gene-editing and other serious diseases. The business model centers on high-margin specialty drugs with strong intellectual property protection.
Where the stock trades today
The shares of Vertex Pharma (US92532F1003) most recently traded on Nasdaq at around $451 per share in regular trading, based on the latest available closing data from 06/18/2026 16:00 ET.
Key facts on Vertex Pharma stock
- Company: Vertex Pharmaceuticals Inc.
- ISIN: US92532F1003
- WKN: 882807
- Ticker: VRTX
- Venue: Nasdaq
- Price (as of 06/18/2026, 16:00 ET): 451.63 USD
- Market cap: 116,000,000,000 USD (as of 06/18/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: Standard & Poor's 500 index (S&P 500)
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
